LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present new preclinical data for its proprietary Axiomer™ RNA editing
… Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 15, … in Japan against a patent directed to its ADAR-mediated RNA editing platform Axiomer™. The opposition was filed in …
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing OligonucleotidesPreclinical proof of concept for the Company’
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will
… ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly … to up to five targets u sing ProQR’s proprietary Axiomer ® RNA editing platform ProQR to receive $ 5 0 million …
… ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform LEIDEN, Netherlands & CAMBRIDGE, Mass., … call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently …
… and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration Partnership focused on utilizing … RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced a …
… ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB LEIDEN, the … ProQR will deliver a presentation on the Axiomer ® RNA editing technology during the TIDES: Oligonucleotide and …